QUANTUM NUMBERS CORP.

Interim Management Discussion and Analysis

As at September 30, 2020

1. SCOPE OF MANAGEMENT'S FINANCIAL ANALYSIS

The following analysis should be read in conjunction with the annual financial statements, including accompanying notes, of Quantum Numbers Corp. ("the Company") for the year ended December 31, 2019. The unaudited condensed interim financial statements for the quarter ended September 30, 2020, including comparative figures, have been prepared in accordance with IFRS applicable to the preparation of interim financial statements, including IAS 34, *Interim Financial Reporting*. All amounts are in Canadian dollars unless otherwise indicated.

1.1 FORWARD LOOKING STATEMENTS

The sections of this management discussion and analysis ("MD&A") on the Company's strategy and action plan, its intellectual properties, development and financial reporting reflecting management's current expectations contain "forward-looking statements." Such statements should be understood in context, particularly statements that reflect the Company's opinions, estimates and expectations about future events or results. Such forward-looking statements are subject to certain factors and involve some risks and uncertainties. There can be no assurance that such statements will prove to be accurate. Factors that could cause future results, activities and events to differ materially from those expressed or implied by such forward-looking statements include, but not limited to, possibility or not to obtain the patent, time required to obtain such patent, risks inherent in the hi-tech industry, and the time it will take for the industry to be ready to move to quantic solutions. These risks and uncertainties are described in this MD&A and also the annual information form filed on SEDAR.

1.2 INCORPORATION, NATURE OF OPERATIONS AND GOING CONCERN

Quantum Numbers Corp. (the "Company" or "Quantum") was incorporated under the *Business Corporations Act* of Ontario on July 19, 2007.

The head office, principal address and records office of the Company are located at 3755 E Blvd Matte, suite 201, Brossard, Québec, J4Y 2P4. The Company is a developer of a new generation of cryptographic solutions pursuant to the acquisition of intellectual property.

The business of technology involves a high degree of risk and there can be no assurance that projects under research and development will proceed through to achieve commercialization. Risks related to the value of the Company's intangible assets, completing proof of concept studies, protecting intellectual property rights, the ability of the Company to raise alternative financing, and risks inherent to new technologies, such as risk of obsolescence, slow adoption and competing technological advances. Changes in future conditions could require material impairment of assets.

These condensed interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") on a going concern basis, which contemplates that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. Since its incorporation, the Company has accumulated a deficit of \$6,016,420 (December 31, 2019 - \$6,224,366) and during the period ended September 30, 2020, incurred a net loss and comprehensive loss of \$409,679 (September 30, 2019 - \$502,053). The Company does not currently have available resources and liquidity to fully execute its business plan over the next 12 months and is dependent on the Company's ability to raise additional finances to fund its operations. The above factors indicate a material uncertainty that may cast a significant doubt as to the Company's ability to continue as a going concern.

1.2 INCORPORATION, NATURE OF OPERATIONS AND GOING CONCERN (Continued)

These condensed interim financial statements have been prepared on a going-concern basis which contemplates that the Company will continue in operation in the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. This assumption is based on the current net assets of the Company and management's current operating plans.

These condensed interim financial statements do not reflect the adjustments to the carrying values of assets and liabilities, the reported amounts of expenses and the classification of statement of financial position items if the going concern assumption was deemed inappropriate. Management did not take these adjustments into account as it believes in the validity of the going concern assumption.

The Company's financial year ends on December 31.

The Company intends to patent its technologies wherever it is required. In the meantime, to ensure sufficient cash flow until market readiness, the Company is looking at M&A transactions to achieve its objectives.

1.3 CHANGES IN SIGNIFICANT ACCOUNTING POLICES

These condensed interim financial statements were prepared in accordance with standard IAS 34 - Interim Financial Reporting and do not include all of the information required for a full set of financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"). They, however, include specific complimentary notes in order to provide information necessary to assess the financial situation of the Company at period end since its last annual financial statements dated December 31, 2019.

At the date of authorization of these condensed interim financial statements, management believes that there are no new standards, amendments and interpretations to existing standards that have been published by the IASB, but are not yet effective, which could materially impact the Company's financial statements.

1.4 SENIOR MANAGEMENT CHANGES

On July 8,2020, Mr. Marc Rousseau was appointed as CEO of the Company following the resignation of Mr. Jean Charles Phaneuf as Chief Executive Officer and Director of the Company. Mr. Rousseau is a Director of the Company since September 6, 2017.

On August 1, 2020, Mr. Pierre-Paul Samson was appointed as Chairman of the Board. Mr. Samson is a Director of the Company since September 6, 2017.

Furthermore, in order to reduce expenses, the Board of Directors has decided to temporarily lay off the Chief Financial Officer, Pierre C. Miron. Mr. Miron remains as Director of the Company and will be reinstated as soon as the financial situation will improve.

On November 19, 2020, the Company announced the resignation of Pierre C Miron as Board Member and Secretary. Mr. Rousseau will combine the duty of CEO and CFO. Mr. Luc Paquet, Director, is taking over the position of Secretary. In addition, the temporary lay-off of Mr. Miron's position as CFO has been converted to a permanent lay-off.

1.5 COMPANY OVERVIEW AND STRATEGY

On August 3, 2016, the Company entered into an Intellectual Property Assignment Agreement with Société de Commercialisation des Produits de la recherche appliquée SOCPRA Sciences et Génie SEC ("SOCPRA") and its inventors by issuing a total of 6,000,000 common shares of the Company at a fair value of \$0.05 per share, representing a total fair value of \$300,000. The Company also reimbursed \$13,838 to SOCPRA for the professional fees associated with the protection of the patent ("Acquisition").

In August 2018, the Company received from the United States Patent and Trademark (USPTO), its first patent on a portion of its application. The Company also received a notice of allowance for the second patent, which was issued on January 1, 2019. Continuation requests have been filed for both patents in order to pursue the acceptance of the claims not accepted, which is why the Company's patents are still at the patent pending stage In the United States. Both applications are still under review with the European Patent Office. The Company's first patent was granted in full from Russia in December 2018.

Until the expiry of the last patent rights, the Company will pay to SOCPRA a royalty of 5% calculated on the net sales price of products sold by the Company. The royalty shall be calculated on a 12-month basis starting on the effective date and shall be paid by the Company to SOCPRA within 90 days following the expiry of each reference year. The Company may have an option to buy back the royalties in the future at terms and conditions to be agreed upon by both parties. Pursuant to the IP Agreement, if the Company did not find or develop a commercial application within three years, 50% of the intellectual property would be transferred back to SOCPRA. As the Company found a commercial application within three years, 50% of the intellectual property shall not be transferred.

The Acquisition was not considered to be a business combination and was accounted for as an asset acquisition. Total purchase price of \$300,000, finder's fees of \$30,000 and transaction costs of \$116,112, which includes the reimbursement of \$13,838 above, totalling \$446,112, were capitalized to intellectual property.

INTELLECTUAL ACTIVITIES

Since Quantum Numbers Corp. changed to quantum hi-tech Intellectual Property, the primary management objective was to strengthen the Company in the following three sectors of activities:

Technology

In order to stay focused on our primary objective, which is to make our technology accessible as rapidly as possible to potential clients and partners, and secured regarding its effectiveness and ensuring that the Intellectual Property is well protected, we are closely working with l'École de Technologie Supérieure ("ETS") in order to maximize the potential and security of our technology. We are putting in place a program to develop complementary metal-oxide semiconductor ("CMOS") implementations with ETS to ensure a greater competitiveness. Subsequent to December 31, 2019, we were awarded a subsidy from the Quantum Province of Quebec program to develop 3 different CMOS implementations.

In regards to our second technology "Method and System for creating a Random Bit Sample", this technology is a method that quantifies the randomness of our signal, a perfect complement to our first technology.

Towards the end of 2019, we decided that it would be beneficial to work on a CMOS version. The Company filed a grant form with a new Provincial Program. The grant was accepted. However, the Company does not have all the details as of yet. The Company only knows that the grant covers between 40% and 60% of the eligible expenses.

1.5 COMPANY OVERVIEW AND STRATEGY (Continued)

INTELLECTUAL ACTIVITIES (Continued)

Technology (Continued)

The Company's latest R&D breakthrough in August 2020 is the achievement of a successfully operational prototype that can reach 300 Mbps of random bits with only the digital components limiting the throughput.

Patent

As the Company must obtain its Patent to pass the introduction level with potential clients, it was then decided to work with the Company's Patent Agent to assess the patentability of our technology. The Company received the final report that indicates that it should continue the National Phase as planned. By doing the legwork and research at the stage of the patentability report, the Company was able to respond rapidly to the European Patent Office ("EPO") investigator. Furthermore, that research also allowed us to develop a second Patent that the Company filed. Please refer below for the status.

Status of patents

First Request Method for generating random numbers and associated random number generator

Country	<u>Status</u>
United States	Patent granted. A partial Patent was granted on August 7, 2018. The second and final portion was granted on October 8, 2019.
Russia	Patent granted on January 16, 2019.
European Patent Office	EPO granted the Patent on February 2, 2020, and the dispute period for all the countries ended on November 2, 2020. We have not received any dispute as of today.
Australia	Patent granted in June 2020.
Thailand	The deadline to request an examination report is November 15, 2022.
Canada, Brazil, India, Indonesia, Republic of Korea, Vietnam, China	For all these countries, we requested the examination and we are awaiting the examiner's response.

1.5 COMPANY OVERVIEW AND STRATEGY (Continued)

INTELLECTUAL ACTIVITIES (Continued)

Status of patents (Continued)

Second Request Method and system for generating a random bit sample

Country	<u>Status</u>
European Patent Office	EPO granted the Patent on October 23, 2019, and there has been no dispute from any countries which are members of the EPO.
United States	Patent granted.
All the countries where our first patent was registered, with the addition of Japan.	In early June, 2020, we registered in all the countries where our first patent was registered, with the addition of Japan. We are still waiting for each examiner's responses.

Market

For the past two years, the Company focused its resources in developing its key IP position to align a successful venture in the emerging Quantum Random Number Generator ("QNRG") market. The National Institute of Standards and Technology Post Quantum Cryptography Standards Committee is still working on related protocols and we believe to have the right attributes to fulfill the future requirements for target markets.

Subsequent to December 31, 2019, the outbreak of the novel strain of coronavirus had the effect of postponing the GSMA MW indefinitely. The attendance to this conference and others in the IT security industry is key to assess our position and initiate early adopter agreements with target markets. For the moment, we are monitoring the situation and will resume as soon as conferences state their position.

Since March 2018, we have not seen any transactions of significant value in our market. In summary, we work closely with the ETS with respect to the technology and adaptation to the needs of potential markets. After reaching key milestones, such as a successful CMOS implementation, we would be able to propose specific solutions to potential markets.

During the third quarter of this fiscal year, the Board of Directors further analyzed and identified the most prevalent industries where the Company's distinct QRNG patented technology will be most needed and accepted with its high levels of security benefits. According to our latest research, we foresee a compelling industry fit with the Healthcare Industry.

1.6 **HIGHLIGHTS**

As at September 30, 2020, the Company had a working capital deficiency of \$101,334 compared to a working capital of \$251,199 on December 31, 2019.

1.7 <u>INTELLECTUAL PROPERTY</u>

The carrying amount can be analyzed as follows:

	Balance as at		Balance as at
	December 31,		September 30,
	2019	Additions	2020
	\$	\$	\$
Cost			
Acquisition of SOCPRA license	446,112	-	446,112
Development costs	199,967		199,967
	646,079	-	646,079
Accumulated amortization			
Amortization	5,194	16,699	21,893
Carrying amount	640,885	16,699	624,186

In October of 2019, when available for use, the Company has commenced amortizing the license on a twenty-year basis. No amortization was taken on the development costs as these assets are not yet available for use.

1.8 SELECTED FINANCIAL INFORMATION AND OPERATING RESULTS

	Three-month periods ended September 30			nth periods eptember 30
	2020	2019	2020	2019
	\$	\$	\$	\$
Expenses				
Salaries	34,131	80,898	172,994	246,454
Development costs	55,917	23,488	108,293	69,921
Professional fees	10,627	5,420	45,263	34,503
Filing and listing fees	6,261	2,988	20,683	12,183
Consulting fees	15,300	-	16,700	3,200
Amortization	5,607	-	16,699	-
Insurance	3,629	3,461	10,870	10,279
Travel expenses	-	18,456	8,085	84,407
Net loss and comprehensive loss for				
the period	(132,789)	(140,307)	(409,979)	(502,053)
Basic and diluted loss per share	(0.002)	(0.002)	(0.007)	(800.0)
Weighted average number of				
common shares outstanding	60,527,838	60,527,838	60,527,838	60,527,838

1.9 BALANCE SHEET

	September 30,	December 31,
	2020	2019
	\$	\$
Total assets	653,285	939,821
Total liabilities	170,230	46,787
Total equity	483,055	893,034

1.10 SUMMARY OF QUARTER RESULTS

The following table sets forth selected quarterly financial information for each of the eight most recently completed quarters.

Three-month period ended	Net loss and comprehensive loss for the period	Basic and diluted loss per share
	\$	\$
September 30, 2020	(132,789)	(0.002)
June 30, 2020	(119,342)	(0.002)
March 31, 2020	(157,848)	(0.003)
December 31, 2019	(161,265)	(0.003)
September 30, 2019	(140,307)	(0.002)
June 30, 2019	(176,690)	(0.003)
March 31, 2019	(185,056)	(0.003)
December 31, 2018	(215,707)	(0.004)

1.11 FINANCIAL SITUATION

LIQUIDITY

As of September 30, 2020, the Company had a working capital deficiency of \$101,334 compared to a working capital of \$251,199 on December 31, 2019. The decrease results mainly from operating expenses incurred.

CASH FLOWS

Company's operating activities used \$20,118 in the three-month period ended September 30, 2020 compared to \$136,213 for the same period in 2019. The decrease in cash flows used results mainly from the decrease in non-cash working capital items.

RESULTS OF OPERATION

The main expenses for the three-month and nine-month period ended September 30, 2020 were salaries for amount of \$34,131 and \$172,994, development costs for an amount of \$55,917 and \$108,293, professional fees for an amount of \$10,627 and \$45,263, filing and listing fees for an amount of \$6,261 and 20,683\$, consulting fees for an amount of \$15,300 and \$16,700 and amortization for an amount of \$5,607 and \$16,699.

The main expenses for the three-month and nine-month periods ended September 30, 2019 were salaries for amount of \$80,898 and \$246,454, travel expenses for an amount of \$18,456 and \$84,407, development costs for \$23,488 and \$69,921, professional fees for an amount of \$5,420 and \$34,503, share-based payments for \$nil and \$20,074 and filing and listing fees for \$2,988 and \$12,183.

1.12 CAPITAL INVESTMENT

On October 1, 2020, the Company announced a plan to raise its next round of capital investment for a non-brokered placement.

On November 19, 2020, the Company announced the closing of the private placement round of capital investment after failing to raise the required capital to continue its R&D and operational activities.

1.13 STOCK OPTIONS

The Company's share options are as follows for the reporting periods:

	September 30, 2020		December 31, 2019	
	'-	Weighted		Weighted
	Number	average	Number of	average
	of options	exercise price	options	exercise price
		\$		\$
Balance outstanding,				
beginning of year	4,250,000	0.20	4,480,000	0.20
Granted	-	-	150,000	0.15
Expired	(2,250,000)	(0.28)	(380,000)	(0.12)
Balance outstanding,				
end of year	2,000,000	0.12	4,250,000	0.20
Balance exercisable,				
end of year	2,000,000	0.12	4,250,000	0.20
•				

The weighted average remaining contractual life for options outstanding at September 30, 2020 is 1.77 (2019 - 6.29) years.

The Company recognized an amount of \$nil (2019 - \$20,074) for the period ended September 30, 2020.

The weighted average fair value of the granted options was determined using the Black-Scholes option pricing model and based on the following weighted average assumptions:

	2020	2019
Average share price at date of grant	_	\$0.31
Dividends yield	-	-
Expected weighted volatility	-	125%
Risk-free interest rate	-	1.39%
Expected average life	-	10 years
Average exercise price at date of grant	-	\$0.30

1.13 STOCK OPTIONS (Continued)

Outstanding and exercisable options are as follows:

		Number o	Remaining life	
Expiry Date	Exercise Price	Outstanding	Exercisable	(years)
	\$		_	
November 22, 2021	0.10	700,000	700,000	1.15
April 1, 2022	0.15	150,000	150,000	1.50
December 8, 2022	0.12	1,150,000	1,150,000	2.19
		2,000,000	2,000,000	

1.14 OUTSTANDING SHARE DATA

	November 30, 2020
Common shares Stock options	60,527,838 2,000,000
Otook options	62,527,838

1.15 INTELLECTUAL PROPERTY

"Our technology involves detailed proprietary and engineering knowledge and specific customer adoption criteria. If the Company is not able to effectively protect its intellectual property or cater to specific customer adoption criteria, our business may suffer a material negative impact and could fail."

The success of our company will be dependent on our ability to successfully develop; qualify under current regulations and protect our technologies by way of patents and trademarks. The Company has its Patent Pending in Canada, United States, European Union and in 10 other countries. If we are unable to secure trademarks and patent protection for our intellectual property in the future, or that protection is inadequate for future products, our business may be materially adversely affected.

Further, there is no assurance that our technology does not or will not infringe upon patents, copyrights or other intellectual property rights held by third parties. The Company has mandated its Patent Agent to perform an exhaustive analysis of the Patent and Patent Pending deposited prior to ours, findings should be available very shortly, but all efforts are being made to obtain it sooner. However, we may become subject to legal proceedings and claims from time to time relating to the intellectual property of others in the ordinary course of our business. If we are found to have violated the intellectual property rights of others, we may be enjoined from using such intellectual property, and we may incur licensing fees or be forced to develop alternatives. In addition, we may incur substantial expenses and diversion of management time in defending against these third-party infringement claims, regardless of their merit Successful infringement or licensing claims against us may result in substantial monetary liabilities, which may materially and adversely disrupt our business.

"The Company may be unable to secure or maintain regulatory qualifications for its Technology."

The Company may be unable to secure or maintain regulatory qualifications for its products for some sector of our market. This would limit the ability of the Company to procure patent or other intellectual property protection for its technology and to license or enforce such patents if any.

1.16 RISK AND UNCERTAINTIES

Since March 31, 2020, the outbreak of the novel strain of coronavirus, has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown, as is the efficacy of the government and central bank interventions. It is not possible for the Company to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Company at this time.

Despite these global setbacks, the Company forged ahead with the development of its prototype. In partnership with l'ETS and l'Université de Sherbrooke, our QNRG testing cycles has successfully produced an operational prototype that can achieve 300 Mbps of random bits with only the digital components limiting the throughput. At this point in time, the current prototype is designed and assembled on standard PCB technology using commercially available and off-the-shelf components, as well as quantum tunneling junctions fabricated using standard clean room techniques on a silicon substrate at Université de Sherbrooke. Following months of testing and development, the purely random quantum signal is clearly observable, and its significance is proven and quantifiable. Although the performance of this prototype is conservative, it does make a conclusive and relevant case for its use with Mobile, 5G and IOT applications. The next R&D cycle will aim to further test and prove its scalability and application for Enterprise Cloud and Bitcoin technologies.

The next step will be to proceed with integrating the entire design into an integrated chip using standard CMOS technology. Moving forward, the Company will mandate a selected private sector firm to speed up this next R&D phase, which is scheduled to begin at the end of September 2020.

Other risk factors are discussed in detail in the Company's Financial Statements and MD&A contained in the annual report for the year ended December 31, 2019.

1.17 EVALUATION OF INTERNAL CONTROL OVER FINANCIAL REPORTING

Management maintains a system of internal control over financial reporting to provide reasonable assurance that assets are safeguarded from any loss or unauthorized use and that financial information is reliable and available in a timely manner. They have also designed or had designed internal controls over financial reporting to provide reasonable assurance that financial reporting is reliable and that the financial statements are designed to report financial information in accordance with IFRS.

There were no important changes in the internal control over financial reporting during the ninemonth period ended September 30, 2020, that had or could reasonably be expected to materially affect the internal control over financial reporting ("ICFR").

1.18 RELATED PARTY TRANSACTIONS

The Company's related parties include companies under common control and joint key management, as described below.

Unless otherwise stated, none of the transactions incorporate special terms and conditions and no guarantees were given or received. Outstanding balances are usually settled in cash.

1.18.1 Transactions with key management

The key management of the Company are the members of senior management and the Board. The remuneration for the period of key management include the following expenses:

	2020	2019
	\$	\$
Consulting fees	15,300	3,200
Salaries	166,154	165,555
Share-based payments	<u>-</u>	5,074
	181,454	173,829

An amount of \$15,300 (2019 - \$nil) is due to senior management for unpaid consulting fees and is included in accounts payable and accrued liabilities.

An amount of \$34,154 (2019 - \$6,000) is due to directors for unpaid salaries and is included in accounts payable and accrued liabilities.

1.19 ADDITIONAL INFORMATION AND CONTINUOUS DISCLOSURE

This MD&A is dated November 21, 2019 and complies with Canadian Securities Administrators' Regulation 51-102 respecting continuous disclosure obligations, c. V-1.1, r. 24. The purpose of this MD&A is to help the reader understand and assess the material changes and trends in the Company's results and financial position. It presents Management's perspective on the Company's current and past activities and financial results, as well as an outlook of activities planned for the coming months. The Company regularly discloses additional information through press releases and other reports filed on the Company (www.quantumnumberscorp.com), and SEDAR (www.sedar.com) websites.

- (s) Pierre-Paul Samson, Chairman
- (s) Marc Rousseau, Chief Executive Officer and Chief Financial Officer

Montreal (Quebec), November 30, 2020